Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hill scrutinizes genetic testing firms

This article was originally published in The Gray Sheet

Executive Summary

House Energy and Commerce Committee is investigating three firms that market personalized genetic testing directly to consumers following a high-profile announcement and reversal by Pathway Genomics earlier this month on plans to start selling its test collection kits at Walgreens retail outlets. Bipartisan leaders of the committee sent letters May 19 to 1Pathway, 223andMe and 3Navigenics, each of which sell genetic test sampling kits and testing services via the Internet, requesting documentation in support of the accuracy of the testing services, of sufficient staff training, of appropriate procedures for providing results to patients and handling DNA samples, and of compliance with FDA regulations. Walgreens delayed plans to carry Pathway's sampling kits after FDA made a public case that the firm was bucking agency regulations by offering the kits and services without approval (4"The Gray Sheet" May 17, 2010)

You may also be interested in...

FDA Cites Long-Term Precedent In Blocking Retail Genetic Screening Plans

A particularly public preemptive stance by FDA's in vitro diagnostics oversight office halted Pathway Genomics' plans last week to start selling genetic screening test sample collection kits out of Walgreens stores, but the office's director stresses the move does not signal any changes to its enforcement policy for laboratory-developed tests

Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Flu Vaccine Leader Sanofi Joins Fight Against Covid-19

As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts